Samlyn Capital LLC decreased its position in Impax Laboratories, Inc. (NASDAQ:IPXL) by 2.4% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 554,400 shares of the specialty pharmaceutical company’s stock after selling 13,600 shares during the quarter. Samlyn Capital LLC owned 0.75% of Impax Laboratories worth $8,926,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of IPXL. Massachusetts Financial Services Co. MA increased its holdings in Impax Laboratories by 1.2% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 14,414 shares of the specialty pharmaceutical company’s stock valued at $182,000 after purchasing an additional 171 shares in the last quarter. Laurion Capital Management LP bought a new position in Impax Laboratories in the 1st quarter valued at $183,000. BNP Paribas Arbitrage SA raised its position in Impax Laboratories by 11.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 15,029 shares of the specialty pharmaceutical company’s stock valued at $190,000 after purchasing an additional 1,588 shares during the last quarter. Appleton Partners Inc. MA bought a new position in Impax Laboratories in the 2nd quarter valued at $191,000. Finally, Municipal Employees Retirement System of Michigan raised its position in Impax Laboratories by 1.7% in the 1st quarter. Municipal Employees Retirement System of Michigan now owns 16,880 shares of the specialty pharmaceutical company’s stock valued at $214,000 after purchasing an additional 280 shares during the last quarter. 86.26% of the stock is currently owned by institutional investors and hedge funds.

IPXL has been the topic of a number of recent analyst reports. Canaccord Genuity set a $19.00 price objective on Impax Laboratories and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada set a $17.00 target price on Impax Laboratories and gave the company a “hold” rating in a research note on Thursday, August 10th. Piper Jaffray Companies set a $17.00 target price on Impax Laboratories and gave the company a “hold” rating in a research note on Thursday, August 10th. Cantor Fitzgerald set a $20.00 price target on Impax Laboratories and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on Impax Laboratories in a report on Thursday, September 28th. They issued a “neutral” rating and a $20.00 price target for the company. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $18.70.

Shares of Impax Laboratories, Inc. (NASDAQ IPXL) traded up 5.23% during trading on Wednesday, reaching $22.15. 532,309 shares of the company traded hands. The firm’s market capitalization is $1.59 billion. Impax Laboratories, Inc. has a 12-month low of $7.75 and a 12-month high of $25.70. The company has a 50 day moving average price of $20.58 and a 200 day moving average price of $16.57.

Impax Laboratories (NASDAQ:IPXL) last released its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.14 by $0.04. The company had revenue of $202.08 million during the quarter, compared to the consensus estimate of $195.62 million. Impax Laboratories had a positive return on equity of 9.05% and a negative net margin of 71.08%. The firm’s revenue was up 17.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.21 earnings per share. On average, equities analysts predict that Impax Laboratories, Inc. will post $0.70 EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Samlyn Capital LLC Has $8.93 Million Stake in Impax Laboratories, Inc. (IPXL)” was reported by Marea Informative and is the property of of Marea Informative. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at http://www.mareainformativa.com/samlyn-capital-llc-has-8-93-million-stake-in-impax-laboratories-inc-ipxl/115164/.

Impax Laboratories Profile

Impax Laboratories, Inc is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma.

Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Receive News & Stock Ratings for Impax Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Impax Laboratories Inc. and related stocks with our FREE daily email newsletter.